Tumour necrosis factor-α interacts with biglycan and decorin  by Tufvesson, Ellen & Westergren-Thorsson, Gunilla
Tumour necrosis factor-K interacts with biglycan and decorin
Ellen Tufvesson, Gunilla Westergren-Thorsson
Section for Cell and Matrix Biology, Department of Cell and Molecular Biology, BMC C13, Lund University, 221 84 Lund, Sweden
Received 5 June 2002; revised 2 September 2002; accepted 9 September 2002
First published online 20 September 2002
Edited by Masayuki Miyasaka
Abstract Several interactions of cytokines with extracellular
matrix molecules are mediated by proteoglycans, such as bigly-
can and decorin. Using surface plasmon resonance, we show for
the ¢rst time that tumour necrosis factor-K (TNF-K) binds to
both biglycan and decorin with Kds of 0.81 WM and 1.23 WM
respectively, a binding that was con¢rmed by Scatchard plots
using a solid phase assay. Binding occurs preferentially via the
core protein, shown by lower Kds, 0.26 WM and 0.81 WM for
biglycan and decorin respectively. There was also binding to
dermatan sulphate, with a Kd of 10.53 WM. The function of
this interaction between TNF-K and biglycan and decorin is
not known, but we suggest that the di¡erential localisation of
the proteoglycans enables the cytokines to be immobilised in
di¡erent environments.
. 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Biglycan and decorin are two small proteoglycans, normally
substituted at the N-terminal with two and one chondroitin/
dermatan sulphate (CS/DS) chain respectively, that are
present in the extracellular matrix of connective tissue. They
are both known to bind di¡erent types of collagens. They also
bind to the same binding site on the biglycan/decorin endo-
cytosis receptor [1]. In addition, biglycan is known to bind to
the membrane-bound proteoglycan dystroglycan [2], while de-
corin is known to bind other extracellular matrix components,
such as ¢bronectin and thrombospondin. Most of these inter-
actions are mediated via the core protein, although some in-
teractions can be exerted through the glycosaminoglycans
(GAG) chains.
Many proteoglycans are important mediators of cytokine
binding and have been shown to modulate the biological ac-
tivity of a variety of cytokines. A well-known example is the
binding of transforming growth factor-L (TGF-L) to decorin,
biglycan and ¢bromodulin [3], where it binds to the core pro-
teins. Some investigators suggest a direct inactivation of TGF-
L by decorin. It has been shown that decorin bound to colla-
gen type I ¢bres is still able to bind TGF-L [4,5] suggesting an
immobilisation of TGF-L in the extracellular matrix, keeping
it away from its signalling receptors on the cell surface. Im-
mobilised TGF-L can subsequently become activated by par-
tial proteolysis of decorin [6] or collagen after the action of
matrix metalloproteinases. A similar function for biglycan is
not known, but may well be possible.
Several other cytokines bind matrix molecules, mainly pro-
teoglycans of the heparan sulphate type. A well known exam-
ple is the binding of ¢broblast growth factor-2 to heparan
sulphate chains [7]. Similarly, DS has been shown to bind to
¢broblast growth factor-2 [8], as well as interferon-Q [9]. Func-
tion can be activation, inhibition or activation of subsequent
intracellular signalling of respective growth factor receptor.
However, little is known about the binding of tumour ne-
crosis factor-K (TNF-K) to extracellular matrix molecules.
TNF-K is a key mediator of in£ammatory processes, and is
found to act at sites of in£ammation. We have previously
shown that TNF-K changes the expression of proteoglycans,
especially that of biglycan in lung ¢broblasts [10], and thereby
gives rise to a remodelling of the connective tissue. It has also
recently been shown that TNF-K binds to the matrix mole-
cules ¢bronectin and laminin and complexed in the extracel-
lular matrix functions as a pro-adhesive cytokine augmenting
the adhesiveness of in¢ltrating leukocytes [11,12].
In the present study we have investigated the ability of
biglycan and decorin to interact with TNF-K. We show that
both biglycan and decorin interact via their core protein to
TNF-K, as well as via their DS chains.
2. Materials and methods
2.1. Puri¢cation of tissue-derived biglycan, decorin, DS and CS
Biglycan and decorin were puri¢ed from bovine sclera as described
previously [13]. DS (iduronic acid content of 95%) was puri¢ed from
porcine skin [14], and CS was puri¢ed from horse nasal septum [15],
the two being termed DS-18 and CS-4 respectively. 125I radiolabelling
of CS and DS was performed as described previously [16].
To remove the GAG chains, proteoglycans were digested with
chondroitin ABC lyase (EC 4.2.2.4, Seikagaku Kogyo, Tokyo, Japan).
2.2. Puri¢cation of recombinant biglycan and decorin
Recombinant human biglycan and bovine decorin were produced in
HeLa cells and Chinese hamster ovary cells, respectively [17]. Puri¢-
cation of proteoglycans was performed by using a Q-Sepharose
(Amersham Pharmacia Biotech) column eluting the proteoglycans
with a gradient of 0.1^1 M NaCl [18]. For 35S radiolabelling of pro-
teoglycans, cells were grown in the presence of 50 WCi/ml [35S]sulphate
and puri¢ed as above.
After chondroitin AC-1 lyase (EC 4.2.2.5, Seikagaku Kogyo, To-
kyo, Japan) digestion of biglycan and decorin, analysis of the iduronic
acid content was carried out on a Bio-Gel P6 column as previously
described [19]; the iduronic acid content was calculated [20] to be
around 60%.
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2.3. Interaction studies using surface plasmon resonance
All measurements were performed with a BIAcore 2000 System.
Recombinant human TNF-K and TGF-L (from RpD Systems,
Abingdon, UK) were immobilised on sensorchips Pioneer B1 with a
1:1 mixture of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and
N-hydroxysuccinimide, as recommended by the manufacturer (BIA-
core AB, Uppsala, Sweden). The remaining active groups were
blocked with 1 M ethanolamine hydrochloride at pH 8.5. Proteogly-
cans were diluted in 0.01 M Tris, 0.15 M NaCl, 0.005% (v/v) surfac-
tant P20 (BIAcore AB), which was also used as the running bu¡er, to
a ¢nal concentration of 5^250 Wg/ml, and injected over the TNF-K
surface at 40 Wl/min. BIAevaluation 3.1 software was used for a⁄nity
analysis according to a 1:1 binding model.
2.4. Solid phase assay of interactions
For the Scatchard analysis, 250 ng/ml recombinant human TNF-K
was adsorbed overnight onto microtitre plates (Maxisorb, Nunc, Ros-
kilde, Denmark). Wells were blocked for 2 h with 1% bovine serum
albumin in Tris-bu¡ered saline to avoid non-speci¢c interactions. Ra-
diolabelled biglycan (0.5^8 Wg) and decorin (0.1^2 Wg) were added to
the wells in a range of concentrations diluted in blocking bu¡er sup-
plemented with 0.05% Tween, and incubated overnight. The amount
of bound proteoglycans was measured by a LKB Wallac (Turku,
Finland) liquid scintillation counter, and the non-speci¢c binding
was subtracted.
A similar procedure was used in the additional binding experiments.
Recombinant human TNF-K was added to each well in di¡erent con-
centrations (0^500 ng/ml) and the radiolabelled biglycan (2^8 Wg) or
decorin (0.5^2 Wg), DS or CS (1^2 Wg) were added.
2.5. Statistical methods
Mean valuesN S.E.M. were calculated.
3. Results
3.1. Interactions studied by surface plasmon resonance
Di¡erent concentrations (5^250 Wg/ml) of tissue-derived bi-
glycan and decorin, as well as DS and CS, were applied at a
constant £ow to the TNF-K surface. Both biglycan (Fig. 1A)
and decorin (Fig. 1B) showed a clear binding to TNF-K, with
biglycan binding to a somewhat larger extent, resulting in Kds
of 0.81 ( N 0.28) WM and 1.23 ( N 1.07) WM respectively. To
determine the speci¢city of the binding, the core proteins of
biglycan and decorin were applied to the TNF-K surface after
digestion with chondroitinase ABC. In this case, the core pro-
tein of both biglycan (Fig. 1C) and decorin (Fig. 1D) bound
to the TNF-K surface to a larger degree than the intact, un-
digested proteoglycan. Biglycan core bound to a larger degree
than decorin core. The Kds of biglycan and decorin changed
Fig. 1. Interaction of TNF-K to biglycan and decorin by surface plasmon resonance. Tissue-derived biglycan (A) and decorin (B) was injected
over a TNF-K surface. Insets in A and B show the £ow over a surface with immobilised TGF-L. Biglycan and decorin were also subjected to
digestion with chondroitinase ABC prior to injection over the TNF-K surface (C and D respectively). Each chromatogram shows seven di¡erent
analyte concentrations of 0, 5, 10, 25, 50, 100 and 250 Wg/ml. Arrows indicate the injection start and end points. One representative experiment
is shown, n=3^5.
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to 0.26 ( N 0.08) WM and 0.81 ( N 0.59) WM respectively, indi-
cating a stronger binding of the core proteins to TNF-K com-
pared to the intact, undigested proteoglycans. Injections with
chondroitinase ABC alone gave no signal, verifying the enzy-
me’s lack of binding to TNF-K.
We also observed that there was no di¡erence in binding to
TNF-K between the native recombinant and non-native, tis-
sue-derived proteoglycans (data not shown), excluding e¡ects
of structural changes during puri¢cation.
To further evaluate the binding between TNF-K and bigly-
can and decorin, di¡erent GAG chain compositions, DS and
CS, were applied to the TNF-K surface. DS bound to TNF-K
in a similar manner as the core protein, albeit to a lesser
degree (Fig. 2A) while CS did not bind at all (Fig. 2B).
This binding of DS to TNF-K showed a Kd of 10.53
( N 5.61) WM. From this we can conclude that both biglycan
and decorin bind TNF-K preferentially via their core proteins,
but also via their DS chains.
These results were compared to the data published on
TGF-L binding to biglycan and decorin [3]. Our experiments
showed that both biglycan (inset in Fig. 1A) and decorin
(inset in Fig. 1B) bound to TGF-L as expected, with Kds of
1.57 WM and 0.12 WM respectively, in accordance with the
previous study [3].
3.2. Solid phase assay of interactions
The Kd values of the binding of biglycan and decorin to
TNF-K were also analysed by Scatchard plots in order to
compare the surface plasmon resonance results. The Scatch-
ard plots for the binding of biglycan (Fig. 3A) and decorin
(Fig. 3B) to TNF-K gave Kds of 0.21 ( N 0.083) WM and 0.054
( N 0.016) WM respectively, which is in accordance with Kd
values obtained by surface plasmon resonance.
In addition, radiolabelled recombinant biglycan, decorin
and tissue-derived DS showed binding to TNF-K that had
been added to wells in di¡erent concentrations. Although we
do not know how much of the added TNF-K was adsorbed, it
was possible to con¢rm the binding results obtained using
surface plasmon resonance. The amount of bound proteogly-
can, both biglycan and decorin, was shown to be increased
with increasing amount of added TNF-K (Fig. 4A,B). More-
over, there was a signi¢cant increase in speci¢c binding of DS.
CS did not bind at all, showing the importance of iduronic
acid content, which was also observed by surface plasmon
resonance (Fig. 4C).
Fig. 2. Interaction of TNF-K to DS and CS by surface plasmon resonance. Tissue-derived DS (A) or CS (B) was injected over a TNF-K sur-
face. Each chromatogram shows seven di¡erent analyte concentrations of 0, 5, 10, 25, 50, 100 and 250 Wg/ml. Arrows indicate the injection
start and end points. One representative experiment is shown, n=3^5.
Fig. 3. Scatchard plots of the binding of radiolabelled recombinant
biglycan and decorin to TNF-K. Recombinant human TNF-K was
added to microtitre plates at a concentration of 250 ng/ml.
[35S]Sulphate-labelled recombinant biglycan (A) or decorin (B) was
allowed to interact, and bound material was quanti¢ed as radioac-
tivity. Bound material was plotted against bound/free material. One
representative experiment is shown, n=4.
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4. Discussion
The data presented here show for the ¢rst time an interac-
tion between the cytokine TNF-K and the small proteoglycans
biglycan and decorin. We also demonstrate that TNF-K pref-
erentially uses the core protein of biglycan and decorin as a
speci¢c binding site, demonstrated by the stronger a⁄nity of
the core protein compared to the intact proteoglycan. In ad-
dition, there is also a certain degree of binding of TNF-K to
DS chains, although this is weaker than the binding to the
core protein. The DS chains display more changes in con¢g-
uration due to a more mobile structure due to its iduronic
acid content compared to the more rigid structure of CS.
Thus the waving DS chain has the possibility of ¢rst catching
the TNF-K molecules and subsequently allowing them to in-
teract more speci¢cally and more strongly to the protein
cores.
We also compared binding of tissue-derived proteoglycans,
puri¢ed under denaturing conditions, to native recombinant
proteoglycans. Previously, the importance of secondary struc-
ture in some of the interactions of biglycan was demonstrated
[21]. We therefore used non-native, tissue-derived biglycan
and decorin (fully glycosylated and with an iduronic acid
content of 50% compared to glucuronic acid) in comparison
with native, recombinant biglycan and decorin (not fully gly-
cosylated with an iduronic acid content of 60% compared to
glucuronic acid). In this case, we showed that there was no
di¡erence in the binding of TNF-K to either native or non-
native biglycan and decorin.
Biglycan and decorin are di¡erently epimerised in di¡erent
tissues, resulting in a varying iduronic acid content. For ex-
ample, human lung ¢broblasts secrete DS with an iduronic
acid content of about 75% compared to glucuronic acid
[19], while in human embryonic skin ¢broblasts it is only
21% [22]. Di¡erent tissues have di¡erent levels of iduronic
acid and we therefore hypothesise that in some tissues this
can give biglycan and decorin a stronger a⁄nity for TNF-K.
This in turn may a¡ect the in£ammatory activities of the
cytokine di¡erently.
This is the ¢rst time the interactions of the pro-in£amma-
tory cytokine TNF-K with proteoglycans have been reported.
TNF-K is upregulated early in in£ammatory processes, as is
TGF-L. Similarly, biglycan is upregulated during early in£am-
mation, while decorin is downregulated. In the later stages of
in£ammation, when ¢brotic lesions are formed, biglycan is
downregulated and an upregulation of decorin is observed.
This has been demonstrated in vivo in several pathological
processes such as asthma [23] and systemic sclerosis [24]. It
is well known that cytokines in£uence the expression and
turnover of speci¢c matrix molecules. We have previously
shown that TNF-K upregulates the expression of biglycan
and downregulates the expression of decorin in lung ¢bro-
blasts [10]. These matrix molecules are located di¡erently,
with biglycan having a pericellular location while decorin is
bound to the collagen network [25]. Though both biglycan
and decorin bind to TNF-K, the binding could have di¡erent
functions. One possibility is that decorin functions as a reser-
voir for sequestering TNF-K out in the extracellular matrix. In
in£ammation, there is an increase in the expression of TNF-K,
as well as a decrease in decorin that reduces this reservoir,
resulting in an additional release of TNF-K. Partial proteol-
ysis of decorin after the action of matrix metalloproteinases
could be the explanation for releasing immobilised TNF-K [6].
Furthermore, the upregulation of biglycan, which at its peri-
cellular location binds TNF-K, could augment a higher con-
centration of TNF-K closer to the cell, promoting association
of TNF-K to its cell surface receptors.
Furthermore, our data show that there is no signi¢cant
di¡erence in the binding of TNF-K to biglycan compared to
decorin. This is in contrast to the previously reported binding
of TGF-L to biglycan and decorin [3], which shows a stronger
Fig. 4. Binding of radiolabelled recombinant biglycan and decorin
to TNF-K in solid phase assay. Recombinant human TNF-K was
added to microtitre plates at di¡erent concentrations (0^500 ng/ml).
[35S]Sulphate-labelled recombinant biglycan (A) and decorin (B) and
[125I]iodine-labelled DS and CS (C) were allowed to interact, and
bound material was quanti¢ed as radioactivity. All values were plot-
ted against added concentration of TNF-K. Data are shown as the
meanNS.E.M., n=3^10.
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binding to the latter proteoglycan. In contrast to our data,
where the binding occurs via both the GAG chain and the
core protein, the interaction with TGF-L has been shown to
be mediated only via the core protein, favouring decorin due
to only one GAG chain as steric hindrance. Interestingly,
decorin could be used to inhibit TGF-L-induced lung ¢brosis
in rats while biglycan could not [26]. We conclude that this
di¡erence in binding a⁄nity in the interactions between di¡er-
ent proteoglycans and cytokines could be of importance in
future therapies.
In summary, we conclude that immobilisation of cytokines
in the extracellular matrix in£uences their possibility to reach
their cell surface receptors during di¡erent pathological con-
ditions.
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